臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"tai w t"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 1-50 / 66 (共2页)
1 2 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-06-27T07:01:48Z	Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer	Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; Yuan A.; Shiau C.-W.; CHONG-JEN YU; Chen K.-F.
臺大學術典藏	2022-05-05T03:09:24Z	Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3	CHAO YUAN HUANG; Lin C.-S.; Tai W.-T.; Hsieh C.-Y.; Shiau C.-W.; Cheng A.-L.; Chen K.-F.
臺大學術典藏	2022-05-05T03:09:23Z	A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3	CHAO YUAN HUANG; Tai W.-T.; Hsieh C.-Y.; Hsu W.-M.; Lai Y.-J.; Chen L.-J.; Shiau C.-W.; Chen K.-F.
臺大學術典藏	2022-05-05T03:09:21Z	Dovitinib acts as a novel radiosensitizer in hepatocellular carcinoma by targeting SHP-1/STAT3 signaling	CHAO YUAN HUANG; Tai W.-T.; Wu S.-Y.; Shih C.-T.; Chen M.-H.; Tsai M.-H.; Kuo C.-W.; Shiau C.-W.; Hung M.-H.; Chen K.-F.
臺大學術典藏	2022-01-24T09:31:35Z	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition	Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; CHUN-JEN LIU; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S.
臺大學術典藏	2022-01-24T09:31:23Z	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis	Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; CHUN-JEN LIU; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; Kao J.-H.
臺大學術典藏	2021-09-04T06:11:25Z	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition	Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏	2021-09-04T06:10:55Z	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis	Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; JIA-HORNG KAO
臺大學術典藏	2021-09-01T01:54:12Z	Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3	Chen K.-F.; Tai W.-T.; Liu T.-H.; Huang H.-P.; Lin Y.-C.; Shiau C.-W.; Li P.-K.; Chen P.-J.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:54:10Z	Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf	Chen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; ANN-LII CHENG; Chen P.-J.; Shiau C.-W.
臺大學術典藏	2021-09-01T01:54:10Z	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells	Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; Hsu C.-H.; Chen P.-J.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:54:09Z	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma	Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.
臺大學術典藏	2021-09-01T01:54:03Z	Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3	Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Liu C.-Y.; Ko C.-H.; Lin M.-W.; Chen P.-J.; Chen K.-F.
臺大學術典藏	2021-09-01T01:54:02Z	Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3	Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:57Z	Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells	Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; Chen P.-J.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:52Z	Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells	Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; ANN-LII CHENG; Chen P.-J.; Chen K.-F.
臺大學術典藏	2021-09-01T01:53:51Z	Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody	Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:47Z	Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3	Huang C.-Y.; Lin C.-S.; Tai W.-T.; Hsieh C.-Y.; Shiau C.-W.; ANN-LII CHENG; Chen K.-F.
臺大學術典藏	2021-08-31T06:29:38Z	Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2011) 55(5) (1041�V1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))	Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.
臺大學術典藏	2021-08-31T06:29:36Z	Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2017) 66(3) (666�V668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))	Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.
臺大學術典藏	2021-08-24T06:05:06Z	SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells	CHEN-TI WANG; Lin C.-S.; Shiau C.-W.; Chu P.-Y.; Hsiao C.-C.; Chiang Y.-L.; Tai W.-T.; Chen K.-F.
臺大學術典藏	2021-07-06T02:04:11Z	STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma	Tai W.-T.; Chu P.-Y.; Shiau C.-W.; Chen Y.-L.; Li Y.-S.; Hung M.-H.; Chen L.-J.; PEI-LUNG CHEN; Su J.-C.; Lin P.-Y.; Yu H.-C.; Chen K.-F.
臺大學術典藏	2021-07-03T03:34:40Z	Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf	Chen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; Cheng A.-L.; PEI-JER CHEN; Shiau C.-W.
臺大學術典藏	2021-07-03T03:34:40Z	Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3	Chen K.-F.; Tai W.-T.; Liu T.-H.; Huang H.-P.; Lin Y.-C.; Shiau C.-W.; Li P.-K.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏	2021-07-03T03:34:38Z	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells	Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; Hsu C.-H.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏	2021-07-03T03:34:35Z	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma	Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏	2021-07-03T03:34:30Z	Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity	Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN; Kim I.; Shiau C.-W.
臺大學術典藏	2021-07-03T03:34:29Z	Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists	Su J.-C.; Chen K.-F.; Chen W.-L.; Liu C.-Y.; Huang J.-W.; Tai W.-T.; PEI-JER CHEN; Kim I.; Shiau C.-W.
臺大學術典藏	2021-07-03T03:34:27Z	Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3	Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Liu C.-Y.; Ko C.-H.; Lin M.-W.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏	2021-07-03T03:34:26Z	Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3	Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏	2021-07-03T03:34:25Z	Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells	Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏	2021-07-03T03:34:23Z	Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells	Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; Cheng A.-L.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏	2021-07-03T03:34:22Z	Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody	Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏	2021-07-03T03:34:13Z	SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model	Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏	2021-07-03T03:34:12Z	Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma	Tai W.-T.; Shiau C.-W.; PEI-JER CHEN; Chu P.-Y.; Huang H.-P.; Liu C.-Y.; Huang J.-W.; Chen K.-F.
臺大學術典藏	2021-07-03T03:33:59Z	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition	Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; PEI-JER CHEN; Chen K.-F.; Kao J.-H.; Chen D.-S.
臺大學術典藏	2021-07-03T03:33:49Z	Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))	Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏	2021-07-03T03:33:47Z	Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))	Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏	2021-07-03T03:33:43Z	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis	Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; PEI-JER CHEN; Chen D.-S.; Chen K.-F.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:42Z	Corrigendum to “Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity” (Eur. J. Med. Chem. (2012) 55 (220–227)(S0223523412004497)(10.1016/j.ejmech.2012.07.023))	Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN; Kim I.; Shiau C.-W.
臺大學術典藏	2021-06-24T01:53:53Z	Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis	Su J.-C.; Mar A.-C.; Wu S.-H.; Tai W.-T.; Chu P.-Y.; Wu C.-Y.; Tseng L.-M.; Lee T.-C.; Chen K.-F.; Liu C.-Y.; HAO-CHIEH CHIU; Shiau C.-W.
臺大學術典藏	2021-06-03T06:50:19Z	Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3	Chen K.-F.; Tai W.-T.; Liu T.-H.; HSIANG-PO HUANG; Lin Y.-C.; Shiau C.-W.; Li P.-K.; Chen P.-J.; Cheng A.-L.
臺大學術典藏	2021-06-03T06:50:19Z	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma	Tai W.-T.; Cheng A.-L.; Shiau C.-W.; HSIANG-PO HUANG; Huang J.-W.; Chen P.-J.; Chen K.-F.
臺大學術典藏	2021-06-03T06:50:16Z	Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma	Tai W.-T.; Shiau C.-W.; Chen P.-J.; Chu P.-Y.; HSIANG-PO HUANG; Liu C.-Y.; Huang J.-W.; Chen K.-F.
臺大學術典藏	2021-06-03T06:50:15Z	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition	Su T.-H.;Shiau C.-W.;Jao P.;Liu C.-H.;Liu C.-J.;Tai W.-T.;Jeng Y.-M.;Yang H.-C.;Tseng T.-C.;Hsiang-Po Huang;Cheng H.-R.;Chen P.-J.;Chen K.-F.;Kao J.-H.;Chen D.-S.; Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; HSIANG-PO HUANG; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S.
臺大學術典藏	2021-05-24T07:20:35Z	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition	Su T.-H.; Shiau C.-W.; Jao P.; CHEN-HUA LIU; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S.
臺大學術典藏	2021-05-24T07:20:29Z	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis	Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; CHEN-HUA LIU; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; Kao J.-H.
臺大學術典藏	2021-05-18T08:20:17Z	Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3	CHAO-YUAN HUANG; Lin C.-S.; Tai W.-T.; Hsieh C.-Y.; Shiau C.-W.; Cheng A.-L.; Chen K.-F.
臺大學術典藏	2021-05-18T08:20:15Z	Dovitinib acts as a novel radiosensitizer in hepatocellular carcinoma by targeting SHP-1/STAT3 signaling	CHAO-YUAN HUANG; Tai W.-T.; Wu S.-Y.; Shih C.-T.; Chen M.-H.; Tsai M.-H.; Kuo C.-W.; Shiau C.-W.; Hung M.-H.; Chen K.-F.
臺大學術典藏	2021-05-18T08:20:15Z	A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3	CHAO-YUAN HUANG; Tai W.-T.; Hsieh C.-Y.; Hsu W.-M.; Lai Y.-J.; Chen L.-J.; Shiau C.-W.; Chen K.-F.

显示项目 1-50 / 66 (共2页)
1 2 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 51903293 在线人数 : 1009 教育部委托研究计画计画执行:国立台湾大学图书馆